AKT1 and cancer: had demonstrated that dihydroartemisinin exhibited anti-cancer efficacy in the treatment of SGC7901/DDP cells, and significantly enhanced the levels of autophagy-related proteins such as Beclin-1 and LC3II by inhibiting the PI3K/Akt/mTOR signaling pathway while concurrently downregulated P-gp, thereby increasing sensitivity to cisplatin (112).